Glucuronide prodrugs of janus kinase inhibitors

Abstract

where W1, R1 and A1 are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.

1 - 72 . (canceled) 
     
     
         73 . A pharmaceutical composition comprising a pharmaceutically acceptable-carrier and a compound of formula VII-1: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         74 . The pharmaceutical composition of  claim 73 , wherein the pharmaceutical composition is suitable for oral administration. 
     
     
         75 . The pharmaceutical composition of  claim 73 , wherein the pharmaceutical composition is in the form of a capsule. 
     
     
         76 . The pharmaceutical composition of  claim 73 , wherein the pharmaceutical composition is in the form of a tablet. 
     
     
         77 . The pharmaceutical composition of  claim 73 , wherein the pharmaceutical composition is in the form of a pill. 
     
     
         78 . The pharmaceutical composition of  claim 73 , wherein the pharmaceutical composition is in the form of a lozenge, cachet, dragee, granules, emulsion, elixir, or syrup. 
     
     
         79 . The pharmaceutical composition of  claim 73 , wherein the pharmaceutical composition is in the form of a suspension. 
     
     
         80 . The pharmaceutical composition of  claim 73 , wherein the pharmaceutical composition is in the form of a solution. 
     
     
         81 . The pharmaceutical composition of  claim 73 , wherein the pharmaceutical composition is in the form of a powder. 
     
     
         82 . The pharmaceutical composition of  claim 73 , wherein the pharmaceutical composition comprises from about 0.01 to about 95% by weight of the compound of formula VII-1, or a pharmaceutically acceptable salt thereof. 
     
     
         83 . The pharmaceutical composition of  claim 73 , wherein the pharmaceutical composition comprises from about 0.01 to about 30% by weight of the compound of formula VII-1, or a pharmaceutically acceptable salt thereof. 
     
     
         84 . The pharmaceutical composition of  claim 73 , wherein the pharmaceutical composition comprises from about 0.01 to about 10% by weight of the compound of formula VII-1, or a pharmaceutically acceptable salt thereof. 
     
     
         85 . The pharmaceutical composition of  claim 73 , wherein the pharmaceutical composition comprises from about 0.1 to about 10% by weight of the compound of formula VII-1, or a pharmaceutically acceptable salt thereof. 
     
     
         86 . The pharmaceutical composition of  claim 73 , wherein the pharmaceutical composition comprises from about 0.5 to about 5% by weight of the compound of formula VII-1, or a pharmaceutically acceptable salt thereof. 
     
     
         87 . The pharmaceutical composition of  claim 73 , wherein the pharmaceutical composition comprises from about 0.5 to about 50 mg of the compound of formula VII-1, or a pharmaceutically acceptable salt thereof. 
     
     
         88 . The pharmaceutical composition of  claim 73 , wherein the pharmaceutical composition comprises from about 1 to about 40 mg of the compound of formula VII-1, or a pharmaceutically acceptable salt thereof. 
     
     
         89 . The pharmaceutical composition of  claim 73 , wherein the pharmaceutical composition comprises from about 1 to about 20 mg of the compound of formula VII-1, or a pharmaceutically acceptable salt thereof. 
     
     
         90 . The pharmaceutical composition of  claim 73 , wherein the pharmaceutical composition comprises one or more additional therapeutic agents.